Evidence map›Paper›PMID 40626832›Full record

SynthesisCancer biology & medicine2025

Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma.

Jie Xiang, Yukai Li, Shengmin Mei, Zhiyan Ou, Li Wang, Yang Ke, Zhiwei Li

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie Xiang *Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Yukai Li *Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.
Shengmin Mei *Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Zhiyan Ou *Department of Pathology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.
Li WangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Yang KeDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.ORCID 0000-0001-6560-5180
Zhiwei LiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.ORCID 0000-0001-9366-9552

Funding

Beijing Bethune Charitable Foundation STLKY0089Medical Subject Leader of Yunnan Province (General Surgery) D-2024029National Natural Science Foundation of China 82460461Top Talent Project of Kunming Medical University-Yang Ke, and Kunming Medical University Innovative Program for Postgraduate 2024S305Young and Mid-aged Academic and Technical Leader Reserve Talent Program of Yunnan Province 202205AC160063Yunnan Fundamental Research Project for Excellent Young Scholars 202401AW070003
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC), a highly aggressive liver cancer, poses a large medical care burden worldwide. The prognosis of patients with HCC is poor, owing to recurrence and metastasis after common treatment methods. Therefore, identifying new targets to eliminate HCC cells is critical for treatment of HCC without recurrence. PANoptosis, a novel inflammatory cell death pathway, has become an intensively investigated area in recent years. The concept of PANoptosis has brought new hope for HCC therapy, given recent evidence implicating this form of programmed cell death in cancer progression, prognosis, and resistance to chemotherapy and immunotherapy. Despite increasing reviews describing the role of PANoptosis in various cancer types, to our knowledge, no systematic review has examined the implications of PANoptosis in HCC. Therefore, we sought to provide the first systematic review of the regulatory mechanisms and therapeutic potential of PANoptosis in HCC. We summarize recent progress in exploration of the role of PANoptosis in HCC, particularly regulation of the HCC tumor microenvironment by PANoptosis. Finally, we highlight the potential of PANoptosis-based diagnostic and therapeutic strategies for HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansImmunotherapyPrognosisTumor Microenvironmentcell deathHepatocellular carcinomaPANoptosisPANoptosometumor microenvironment

Identifiers

PMID40626832
PMCPMC12418266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.